The concentration of test inhibitor required for 50% reduction in the measured isozyme activity (IC50) was estimated using GrapPad Prism® software. Samples for in vitro biotransformation GSK J4 mw were obtained following incubation

of DNDI-VL-2098 (10 μM) with microsomes in presence of cofactors, and with hepatocytes for up to 120 min as described for metabolic stability. Samples for in vivo biotransformation were oral PK blood samples at 4, 6 and 8 h post dose from mouse (50 mg/kg), rat (500 mg/kg) and dog (50 mg/kg). All samples were precipitated with acetonitrile, vortex-mixed and centrifuged (1700g, 10 min) and the supernatants were analyzed for Phase I and Phase II metabolites. All in vivo and in vitro samples were analyzed

for DNDI-VL-2098 learn more and internal standard (DNDI-VL-2075, a structural analog) content using a high performance liquid chromatography (HPLC, Shimadzu Prominence, Japan) tandem mass spectrometric (API4000, Applied Biosystems, USA) method. Positive-ion electron spray ionization mode was used and MRM transitions of 360.20/175.00 for DNDI-VL-2098 and 370.20/241.20 for DNDI-VL-2075 (5 μg/mL) were monitored. An isocratic HPLC method with a 4 min run time was employed for analysis. The mobile phase comprised 5 mM ammonium formate and acetonitrile 20:80 (v/v) with 0.05% formic acid and the flow rate was 0.6 mL/min. Separation was achieved using Kromasil® C8 column (4.6 × 50 mm, 5 μ, Chromatographie Service, USA) maintained at 40 °C employing an injection volume of 10 μL for in vivo samples and 5 μL for in vitro samples. In preliminary studies, DNDI-VL-2098 showed some instability in plasma from different species. Acidification of blood samples from dosed animals with many an equal volume of 0.1 M HCl resolved the issue, as bench-top stability of greater than 5 h was achieved; therefore all concentrations were determined in blood. Blood samples were extracted using liquid–liquid extraction (LLE) with methyl tert-butyl ether (MTBE). A 50 μL aliquot of

blood, internal standard (20 μL) and potassium dihydrogen phosphate buffer (100 mM, 50 μL) and 1.25 mL of MTBE were vortex mixed and then centrifuged at 2500g for 5 min. A 1 mL aliquot of supernatant was evaporated under flow of nitrogen gas at 50 °C until dryness, and the residue was reconstituted with 200 μL of mobile phase before analysis. The lower limit of quantification (LLOQ) was 5 ng/mL and the assay was linear over a 1000-fold concentration range. All samples were processed along with calibration curve and quality control samples. An acceptance criterion of ±15% was used for all calibration curve (CC), and quality control (QC) standards except for LLOQ sample where ±20% was the acceptance criteria. Samples were processed by protein precipitation with acetonitrile for all assays except the blood to plasma concentration ratio assay where LLE using MTBE was employed.